Purpose:

Acute myelogenous leukemia (AML) is an aggressive disease with a poor outcome. We investigated mechanisms by which the anti-AML activity of ABT-199 (venetoclax) could be potentiated by dual mTORC1/TORC2 inhibition.

Experimental Design:

Venetoclax/INK128 synergism was assessed in various AML cell lines and primary patient AML samples in vitro. AML cells overexpressing MCL-1, constitutively active AKT, BAK, and/or BAX knockout, and acquired venetoclax resistance were investigated to define mechanisms underlying interactions. The antileukemic efficacy of this regimen was also examined in xenograft and patient-derived xenograft (PDX) models.

Results:

Combination treatment with venetoclax and INK128 (but not the mTORC1 inhibitor rapamycin) dramatically enhanced cell death in AML cell lines. Synergism was associated with p-AKT and p-4EBP1 downregulation and dependent upon MCL-1 downregulation and BAK/BAX upregulation as MCL-1 overexpression and BAX/BAK knockout abrogated cell death. Constitutive AKT activation opposed synergism between venetoclax and PI3K or AKT inhibitors, but not INK128. Combination treatment also synergistically induced cell death in venetoclax-resistant AML cells. Similar events occurred in primary patient-derived leukemia samples but not normal CD34+ cells. Finally, venetoclax and INK128 co-treatment displayed increased antileukemia effects in in vivo xenograft and PDX models.

Conclusions:

The venetoclax/INK128 regimen exerts significant antileukemic activity in various preclinical models through mechanisms involving MCL-1 downregulation and BAK/BAX activation, and offers potential advantages over PI3K or AKT inhibitors in cells with constitutive AKT activation. This regimen is active against primary and venetoclax-resistant AML cells, and in in vivo AML models. Further investigation of this strategy appears warranted.

Translational Relevance

ABT-199 (venetoclax), an anti-BCL2 BH3 mimetic, has recently entered the therapeutic armamentarium for AML treatment. It exhibits modest single-agent activity but is currently approved when combined with hypomethylating agents or low-dose cytarabine. Unfortunately, de novo or acquired resistance to venetoclax often occurs through upregulation of other anti-apoptotic proteins and/or downregulation of pro-apoptotic proteins. The PI3K/AKT/mTOR pathway is frequently upregulated in AML and a dual mTORC1/TORC2 inhibitor, INK128, has been shown to downregulate the antiapoptotic protein, MCL-1. We observed significant synergism between venetoclax and INK128 in various AML cell lines, including those with intrinsic or acquired venetoclax resistance, primary patient AML samples in vitro, as well as in various in vivo models including a patient-derived xenograft (PDX). This regimen showed potential superiority to combinations involving other PI3K/AKT/mTOR pathway inhibitors. Collectively, these preclinical data provide a theoretical foundation for improving the anti-AML activity of venetoclax through combination with dual mTORC1/2 inhibitors.

Acute myelogenous leukemia (AML) is a heterogenous disease driven by deregulation of multiple pathways, including genetic aberrations, mutations, and overexpression of antiapoptotic proteins (1). Despite this heterogeneity, treatment options for AML have been limited to anthracyclines, nucleoside analogs, and alkylating agents until the approval in 2017 of midostaurin targeting the FLT3 mutation. Since then, 8 agents have been approved or reapproved for this disease (1). Of these recent advances, the introduction of the anti-BCL2 BH3 mimetic, venetoclax, has had a major impact on AML treatment (2). Anti-apoptotic BCL2 family members such as BCL2, BCL-xL, BCLW, and MCL-1 are frequently overexpressed in hematologic malignancies, including AML (3). These proteins bind to and sequester pro-apoptotic BCL2 family members such as BAK and BAX that trigger mitochondrial outer membrane permeabilization (MOMP), an irreversible step in apoptotic cell death (4). ABT-737 (navitoclax) was the first-in-class BH3 mimetic to be developed. This agent binds to BCL2, BCL-xL, BCLW, as well as MCL-1 but with a considerably weaker affinity for the latter (5). An orally bioavailable derivative of ABT-737, navitoclax (ABT-263) was subsequently developed but its potential in AML was limited by the risk of severe thrombocytopenia arising from on-target effects of BCL-xL (6). It is not currently used in this disorder.

This limitation stimulated the clinical development of venetoclax that exhibited a pronounced affinity for BCL2 but a much lower affinity for BCL-xL compared with navitoclax (7). Venetoclax displayed modest monotherapy efficacy in AML (8), but was subsequently approved when administered in combination with hypomethylating agents or low-dose cytarabine, providing an additional 5 months overall survival based on the results of a phase III clinical trial for patients not fit for intensive induction chemotherapy (9). As in the case of other targeted agents, de novo or acquired resistance to venetoclax occurs through various mechanisms, including upregulation of other anti-apoptotic proteins (10) and downregulation of pro-apoptotic proteins (11), raising the possibility that combination strategies circumventing these events may be necessary to enhance the therapeutic efficacy of this agent in AML.

The PI3K/AKT/mTOR pathway is frequently upregulated in AML secondary to FLT3, c-KIT, and RAS mutations (12) and inhibitors of PI3K such as idelalisib, copanlisib, and duvelisib have been approved for other hematological malignancies, including chronic lymphocytic leukemia (CLL) and non–Hodgkin lymphoma. The mTOR regulates signals acting through the AKT pathway as well as other cascades involved in energy maintenance and oxidative stress among others (13). mTOR functions as a serine/threonine kinase and participates in two complexes: mTORC1, implicated in RNA translation via 4EBP1 phosphorylation, and mTORC2, whose downstream target is AKT (14). Although mTORC1 inhibitors such as rapamycin have been approved for the treatment of certain solid tumors, for example, renal cell carcinoma (15), they have shown minimal activity in AML, despite displaying activity against leukemia stem cells in preclinical studies (16). It has been proposed that the limited activity of rapalogs reflects the failure to inhibit 4EBP1 and/or feedback activation of PI3K/AKT and MEK/ERK (17, 18). These considerations led to the development of second-generation dual TORC1/2 inhibitors (e.g., AZD2014 and INK128) that may offer advantages over pure TORC1 inhibitors (19, 20). INK128, currently referred to as spanisertib or TAK-228, has shown preliminary efficacy in solid tumors (21) and is currently under investigation in combination approaches (22, 23).

Previously, our group reported that dual mTORC1/2 inhibitors interacted synergistically with the BCL2/BCL-xL inhibitor navitoclax to induce cell death in AML cells through a mechanism involving, at least in part, MCL-1 downregulation (24). However, it would be important to determine whether similar mechanisms are operative in the case of venetoclax, given the approval of this agent in AML and the inability to employ navitoclax in this disease. Currently, mechanistic insights into interactions between dual TORC1/2 inhibitors and venetoclax in human myeloid leukemia cells are essentially lacking. In particular, it is presently unknown whether such a strategy would be effective in cells with high basal AKT activity or with acquired venetoclax resistance. Here, we report that this strategy synergistically induces cell death in AML cells, including those resistant to venetoclax or expressing constitutively active AKT, and is active against primary AML (but not normal) cells as well as in an AML patient-derived xenograft (PDX) model.

Cells and reagents

Human AML cell lines, U937 and MV4–11 (CRL-9591) were purchased from the ATCC, MOLM-13 (DSMZ Cat# ACC-554) and OCI-AML3 (DSMZ Cat# ACC-582) cells were purchased from DSMZ (Brunswick, Lower Saxony, Germany) and maintained as described previously (25). All cell lines were tested for Mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza) routinely. All experiments used logarithmically growing cells (3–4×105 cells/mL).

Venetoclax-resistant MV4–11 and MOLM-13 cells were obtained by culturing in the presence of increasing venetoclax (from 1 nmol/L to 1 μmol/L) concentrations over a period of 2 months.

Venetoclax was a gift from AbbVie. INK128, AZD2014 was purchased from ChemieTek. Copanlisib was purchased from AdooQ. MK2206 was purchased from MedChemExpress (Monmouth Junction). Rapamycin was purchased from Cell Signaling Technology. All drugs were dissolved in DMSO, aliquoted, and stored at −80°C. Final DMSO concentrations did not exceed 0.1%.

Plasmid transfection and virus infection

Lentiviruses were generated in 293T cells by transfecting cells with plasmids, pLX307 MCL-1 plasmid (Addgene #117726, RRID:Addgene_117726)/pCDH-puro-myr-HA-Akt1 (Addgene #46969, RRID:Addgene_46969; ref. 26), psPAX2 (Addgene #12260, RRID:Addgene_12260), and pMD2-VSVG (Addgene #12259, RRID:Addgene_12259). PEI transfection reagents were used. Viral supernatant was collected 2 and 3 days after transfection, filtered through 0.45 μmol/L membranes, and added to U937 and MV4–11 cells in the presence of polybrene (8 μg/mL, Millipore). Puromycin (1.5 μg/mL) was used to treat cells for two days for selection, which eliminated all cells in the uninfected control group. MV4–11 cells lacking BAX, BAK, or BAK/BAX were generated using CRISPR-Cas9 system as previously described (25).

Analysis of cell death

Apoptosis was evaluated by flow cytometry using Annexin V-FITC/PI staining as before (10). Loss of mitochondrial membrane potential and cell death were assessed by double staining with 7-AAD as before (10). Drug concentrations used in cytotoxicity studies were selected on the basis of relatively modest (e.g., generally <20%) single-agent induction of cell death.

For CD34+/CD38/CD123+ and CD34+/CD45dim/SSlow analysis, CD34+ mononuclear cells isolated from patient with AML bone marrows were blocked by TruStain FcX (BioLegend, Cat#422302) on ice for 10 minutes, stained with CD38-PE/Cy7 (BioLegend, Cat#303516), CD123-APC (BioLegend, Cat#306012) and/or CD45-APC-FireTM750 (BioLegend, Cat#304062) on ice for 30 minutes followed by staining with Annexin V-FITC at room temperature for 15 minutes. The percentage of apoptotic (Annexin V+) cells in the CD34+/CD38/CD123+ and CD34+/CD45dim/SSlow population was then determined using a FACSCanto flow cytometer (BD Biosciences).

Immunoprecipitation and immunoblotting

Immunoprecipitation and immunoblotting were performed as previously described (27). The following primary antibodies were used: β-Actin (Sigma-Aldrich, Cat#A2066), AKT (Cat#4691), BAK (Cat#12105S), BAX (Cat#5023S), BCL2 (Cat#15071), BCL-xL (Cat#2762S), cleaved PARP (Cat#9541), cleaved caspase-3 (Cat#9661S), GAPDH (Cat#97166S), γH2A.X (Cat#2577S), phospho-AKT (Ser473; Cat#4060), phospho-4E-BP1 (Thr37/46; Cat#2855), and 4E-BP1 (Cat#9644) from Cell Signaling Technology. BAK AB1 (Cat# AM03100UG) was purchased from Thermo Fisher Scientific. BAX 6A7 (Cat# sc-23959) and MCL-1 (Cat#, sc-74437) were purchased from Santa Cruz Biotechnology.

BAX and BAK conformational change

BAX and BAK conformational changes were assessed as previously described (27).

Isolation of primary AML cells

Bone marrow or peripheral blood samples from patients with AML were obtained with written informed consent from the patients (both male and female, over the age of 18). These studies were conducted in accordance with the Helsinki Declaration. Mononuclear cells were isolated as previously described (28). Normal hematopoietic CD34+ cells were isolated from human umbilical cord blood obtained from patients undergoing normal deliveries. All studies were sanctioned by the Investigational Review Board of Virginia Commonwealth University.

Immunofluorescence

After 16-hour treatment, primary patient mononuclear cells were incubated with 7-AAD (Sigma-Aldrich) and anti-human CD34 antibody conjugated with Alexa-Fluor488 (BioLegend, Cat#343518) for 20 minutes. Slides were then mounted using DAPI (4′,6-diamidino-2-phenylindole) Fluoromount-G (Southern Biotech). PDX bone marrow samples were fixed in 4% formaldehyde for 2 minutes and then blocked with PBX containing 5% BSA. Anti-human CD45-PE/Cy7 (BD Pharmingen, Cat#557748) was used for immunofluorescent staining. Slides were then mounted using DAPI Fluoromount-G (Southern Biotech). Images were captured using an Olympus IX71 Inverted System Microscope with a DP73; 17MP Color Camera.

IHC staining

Femurs from PDX mice were excised for histological examination and fixed in neutral-buffered formaldehyde (10%) overnight at 4°C. Samples were washed with water and decalcified in 10% EDTA (pH 7.4) for 14 days, until they lost normal structural rigidity. The bones were then embedded in paraffin blocks and 5 μmol/L sections were cutoff. Sections were subsequently immunohistochemically processed using anti-CD45 antibodies, and evaluated by histopathology. Sections were visualized and images captured using an Olympus BX41 Fluorescence Microscope with a DP71 Digital Camera.

Animal studies

Animal studies were conducted under an approved protocol by the Virginia Commonwealth University Institutional Animal Care and Use Committee. For the orthotopic murine model, NOD/SCID-gamma mice (The Jackson Laboratory, RRID: IMSR_JAX:005557) were injected intravenously via tail vein with 5×106 luciferase-expressing MV4–11 cells. Eleven days after injection of tumor cells, mice were monitored for AML engraftment using the IVIS 200 imaging system (Xenogen Corporation) as described before (24). Mice were exposed to either oral venetoclax 80 mg/kg, oral INK128 0.5 mg/kg, or combined treatment 3 days/week for 4 weeks. Control animals were administered equal volume of vehicle. Tumor growth was also monitored every other day with an IVIS 200 imaging system. For the flank murine model, NOD/SCID-gamma mice were inoculated subcutaneously with 1×106 U937 cells. From 5 days after injection, mice were treated with oral venetoclax 80 mg/kg, oral INK128 0.5 mg/kg, or combined treatment 3 days/week for 4 weeks or until tumor size reached 17 mm or other humane endpoints occurred. For the PDX model, NOD/SCID-gamma Il3- GM-SF (NSG-SGM3; The Jackson Laboratory; RRID: IMSR_JAX:013062) were inoculated with 4×106 patient cells (#101–03340) via tail vein. After confirming human CD45+ cell engraftment in peripheral blood 59 days after injection, mice were treated with either oral venetoclax 80 mg/kg, oral INK128 0.5 mg/kg, or combined treatment 3 days/week for 6 weeks, after which they were sacrificed and the percentage of human CD45+ cells in bone marrows was assessed.

Statistical analysis

Values represent the means ± SD for at least 3 independent experiments performed in triplicate. The significance of differences between experimental variables was determined using the Student t test or one-way ANOVA with the Tukey's–Kramer multiple comparisons test. The significance of P values is *, P <0.05; **, P <0.01; or ***, P <0.001, wherever indicated. Analysis of synergism was performed by median dose effect analysis using the software Calcusyn (Biosoft; ref. 29). Kaplan–Meier analysis of mouse survival was performed using GraphPad Prism 6 software (RRID:SCR_002798).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. All updated original source data (chiefly Western blot data) are available to the journal and readers via storage on the website OSFHOME with the following web address: https://osf.io/8ak4z/?view_only=254bd20337064f6896d31e7b6a958150.

Venetoclax/INK128 co-administration synergistically induces apoptosis in both sensitive as well as intrinsically resistant human leukemia cell lines

In both venetoclax-sensitive (MV4–11 and MOLM-13) or intrinsically resistant (U937 and AML-3) cell lines, combination treatment with venetoclax and INK128 sharply increased cell lethality at minimally effective single-agent dose levels (Fig. 1A and B; Supplementary Fig. S1A and S1B). In intrinsically sensitive cells, venetoclax concentrations of 5 nmol/L were used, whereas in less sensitive cells, higher but pharmacologically achievable venetoclax concentrations were used (e.g., 0.5–1.0 μmol/L). In each case, combination indices substantially less than 1.0 were obtained by median dose effect analysis (Fig. 1C and D; Supplementary Fig. S1C and S1D), indicating highly synergistic interactions. Similar synergism was observed with an alternative dual mTORC1/2 inhibitor, AZD2014 (Supplementary Fig. S2A–S2D). Interestingly, synergistic interactions were not observed with the selective mTORC1 inhibitor rapamycin (Supplementary Fig. S2E and S2F), and in fact, rapamycin failed to significantly enhance venetoclax-induced apoptosis in U937 and MV4–11 cells, even when administered at considerably higher concentrations compared with those of INK128 (e.g., 5 μmol/L vs. 100 nmol/L; Supplementary Fig. S2G and S2H). Consistent with these findings, co-treatment with venetoclax/INK128 induced pronounced caspase-3/PARP cleavage and increases in the DNA damage response marker, γH2A.X, whereas single agents had minimal effects (Fig. 1E; Supplementary Fig. S1E and S1F).

Figure 1.

Dual BCL2 and mTORC1/2 inhibition synergistically induces apoptosis in intrinsically resistant or sensitive human leukemia cells. A, Intrinsically resistant U937 cells were exposed to venetoclax 2 μmol/L and INK128 200 nmol/L alone or in combination for 24 hours. Apoptosis was assessed by an Annexin V-FITC/PI assay. Error bars, SD of three independent experiments; **, P < 0.01 in each case for values obtained in co-treatment group versus the single-agent treatment group. B, Intrinsically sensitive MV4–11 cells were exposed to venetoclax 10 nmol/L, INK128 100 nmol/L, or combination for 24 hours. Apoptosis was assessed by an Annexin V-FITC/PI assay as above. Error bars, SD for three independent experiments; **, P < 0.01 in each case for values obtained in co-treatment group versus single-agent treatment. #, P < 0.05 in each case for values obtained in single-agent treatment group compared with the control group. A and B, Results represent 3 separate experiments performed in triplicate. C, Median dose effect analysis of U937 cells displaying combination index values less than 1.0, indicating synergistic effects at a dose ratio of venetoclax:INK128 = 2:1. D, Median dose effect analysis in MV4–11 cells displaying combination index values below 1, indicating synergistic effects at dose ratios for venetoclax:INK128 = 1:10. E, Western blot analysis of gamma-H2A.X, PARP, and caspase-3 in MV4–11 and U937 cells following exposure to venetoclax (5 nmol/L for MV4–11, 1 μmol/L for U937), INK128 (50 nmol/L for MV4–11, 100 nmol/L for U937), or combination for 16 hours. Blots were stripped and re-probed with β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Figure 1.

Dual BCL2 and mTORC1/2 inhibition synergistically induces apoptosis in intrinsically resistant or sensitive human leukemia cells. A, Intrinsically resistant U937 cells were exposed to venetoclax 2 μmol/L and INK128 200 nmol/L alone or in combination for 24 hours. Apoptosis was assessed by an Annexin V-FITC/PI assay. Error bars, SD of three independent experiments; **, P < 0.01 in each case for values obtained in co-treatment group versus the single-agent treatment group. B, Intrinsically sensitive MV4–11 cells were exposed to venetoclax 10 nmol/L, INK128 100 nmol/L, or combination for 24 hours. Apoptosis was assessed by an Annexin V-FITC/PI assay as above. Error bars, SD for three independent experiments; **, P < 0.01 in each case for values obtained in co-treatment group versus single-agent treatment. #, P < 0.05 in each case for values obtained in single-agent treatment group compared with the control group. A and B, Results represent 3 separate experiments performed in triplicate. C, Median dose effect analysis of U937 cells displaying combination index values less than 1.0, indicating synergistic effects at a dose ratio of venetoclax:INK128 = 2:1. D, Median dose effect analysis in MV4–11 cells displaying combination index values below 1, indicating synergistic effects at dose ratios for venetoclax:INK128 = 1:10. E, Western blot analysis of gamma-H2A.X, PARP, and caspase-3 in MV4–11 and U937 cells following exposure to venetoclax (5 nmol/L for MV4–11, 1 μmol/L for U937), INK128 (50 nmol/L for MV4–11, 100 nmol/L for U937), or combination for 16 hours. Blots were stripped and re-probed with β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Close modal

Dual mTORC1/2 inhibition inhibits AKT phosphorylation and 4E-BP1 phosphorylation in wild-type and cells expressing constitutively active AKT

INK128 administered (24 hours) alone or in combination with venetoclax in MV4–11 or U937 cells diminished phosphorylation of AKT (downstream of mTORC2) at Ser473 and to a varying extent, phospho-4EBP1 (downstream of both AKT and mTORC1; ref. 30; Fig. 2A). Compatible results were observed at earlier intervals, for example, 6 and 12 hours (Supplementary Fig. S3A and S3B), and in other lines, for example, AML-3 and MOLM-13 (Supplementary Fig. S3C and S3D). For Western blot studies, slightly lower drug concentrations were used to minimize the confounding effects of extensive apoptosis. Corresponding quantitative analysis of cell death is shown in Supplementary Fig. S4.

Figure 2.

Constitutive AKT activation abrogates synergism between venetoclax and copanlisib but not INK128. A, Western blot analysis of MV4–11 and U937 cells for the indicated proteins following exposure to venetoclax (5 nmol/L for MV4–11, 1 μmol/L for U937), INK128 (50 nmol/L for MV4–11, 100 nmol/L for U937), or both for 24 hours. B and C, U937 cells ectopically expressing constitutively active (myristolated) AKT were treated with venetoclax 2 μmol/L, INK128 200 nmol/L, or the combination for 24 hours after which apoptosis was assessed with the Annexin V-FITC/PI assay. Error bars, SD for 3 independent experiments; ns, P > 0.05; */#, P < 0.05; **/##, P < 0.01; ***/###, P < 0.001; D, Western blot analysis of U937 cells for the indicated proteins following exposure to venetoclax 1 μmol/L, INK128 100 nmol/L, or both for 24 hours as in C. E, Annexin V-FITC/PI assay for apoptosis in U937 cells following exposure to venetoclax 2 μmol/L, copanlisib 400 nmol/L, or the combination for 24 hours. Error bars, SD for 3 independent experiments; **, P < 0.01. F, Western blot analysis for the indicated proteins in U937 following exposure to venetoclax 1 μmol/L, copanlisib 200 nmol/L, or both for 24 hours. For Western blot studies, blots were stripped and re-probed for β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Figure 2.

Constitutive AKT activation abrogates synergism between venetoclax and copanlisib but not INK128. A, Western blot analysis of MV4–11 and U937 cells for the indicated proteins following exposure to venetoclax (5 nmol/L for MV4–11, 1 μmol/L for U937), INK128 (50 nmol/L for MV4–11, 100 nmol/L for U937), or both for 24 hours. B and C, U937 cells ectopically expressing constitutively active (myristolated) AKT were treated with venetoclax 2 μmol/L, INK128 200 nmol/L, or the combination for 24 hours after which apoptosis was assessed with the Annexin V-FITC/PI assay. Error bars, SD for 3 independent experiments; ns, P > 0.05; */#, P < 0.05; **/##, P < 0.01; ***/###, P < 0.001; D, Western blot analysis of U937 cells for the indicated proteins following exposure to venetoclax 1 μmol/L, INK128 100 nmol/L, or both for 24 hours as in C. E, Annexin V-FITC/PI assay for apoptosis in U937 cells following exposure to venetoclax 2 μmol/L, copanlisib 400 nmol/L, or the combination for 24 hours. Error bars, SD for 3 independent experiments; **, P < 0.01. F, Western blot analysis for the indicated proteins in U937 following exposure to venetoclax 1 μmol/L, copanlisib 200 nmol/L, or both for 24 hours. For Western blot studies, blots were stripped and re-probed for β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Close modal

To investigate the functional capacity of this strategy to circumvent the effects of AKT overexpression, U937 cells ectopically expressing constitutively active (myristolated) AKT were generated (Fig. 2B). Notably, constitutive AKT activation failed to reduce the lethal effects of the venetoclax/INK128 regimen (P > 0.05), manifested by Annexin V-FITC/PI staining and caspase-3 cleavage (Fig. 2C and D). Consistent with these results, both phosphorylated AKT and 4E-BP1 levels were similarly downregulated in control cells and in two subclones expressing constitutively active AKT.

In view of evidence by our group and others that PI3K inhibitors potentiate the activity of venetoclax in AML and lymphoma cells (31), parallel studies were performed with the PI3K inhibitor copanlisib. In marked contrast with results obtained with INK128, a regimen combining copanlisib and venetoclax was significantly less effective in inducing apoptosis (P < 0.01) in constitutively active AKT cells than in empty-vector (EV) controls (Fig. 2E). Consistent with these findings, CA-AKT cells largely failed to display dephosphorylation of AKT and 4EBP1 or cleavage of caspase-3 following venetoclax/copanlisib exposure, whereas pronounced reductions in p-AKT and p-4EBP1 as well as marked caspase-3 cleavage were observed in EV controls (Fig. 2F).

Finally, parallel results were obtained with the AKT inhibitor MK2206. Specifically, the lethal effects of the MK2206/venetoclax regimen were dramatically attenuated in AKT-CA cells compared with EV controls (Supplementary Fig. S5A). Consistent with these findings, AKT-CA cells exposed to MK2206/venetoclax exhibited reduced dephosphorylation of pAKT and p4EBP1, as well as minimal cleavage of caspase-3 compared with control cells (Supplementary Fig. S5B). Together, these findings raise the possibility that dual mTORC1/2 inhibition may offer advantages over PI3K or AKT inhibition in potentiating venetoclax antileukemic effects, at least in cells displaying basal AKT activation.

Downregulation of MCL-1 plays a functional role in venetoclax/INK128 synergism

Treatment of MV4–11 cells with venetoclax modestly increased MCL-1 expression as shown by Western blot analysis (Fig. 3A), a phenomenon that has previously been observed with this and other BH3-mimetics, for example, ABT-737 (32). However, co-administration of INK128 abrogated this increase and in fact resulted in a net reduction in MCL-1 levels. Similar phenomena were observed with multiple other AML lines, for example, U937, AML-3, and MOLM-13 (Supplementary Fig. S6A–S6C). To gain further insights into the functional role of MCL-1 in venetoclax/INK128 interactions, MV4–11 cells ectopically expressing MCL-1 were used (Fig. 3B). Compared with control EV cells, MCL-1–overexpressing cells displayed significant resistance to combined treatment with the venetoclax/INK128 regimen (Annexin V-FITC/PI; P < 0.01) accompanied by increased expression of MCL-1 (Fig. 3B and C). Very similar results were observed in MCL-1–overexpressing U937 cells, for example, enforced expression of MCL-1 protected cells from venetoclax/INK128-induced lethality in association with diminished MCL-1 downregulation and PARP cleavage (Supplementary Fig. S6D and S6E). These findings argue that MCL-1 downregulation by INK128 contributes functionally to INK128/venetoclax antileukemic synergism.

Figure 3.

Venetoclax/INK128 antileukemic synergism involves MCL-1 downregulation and activation of BAX and BAK. A, Western blot analysis of MCL-1 expression changes in MV4–11 cells following exposure (24 hours) to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination. B, MV4–11 cells ectopically expressing MCL-1 were generated and exposed, along with their empty-vector (EV) counterparts, to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 24 hours. Western blot analysis was then performed to monitor expression of cleaved PARP and MCL-1. C, Annexin V-FITC/PI analysis of EV and MCL-1 overexpressing MV4–11 cells treated with venetoclax 10 nmol/L, INK128 100 nmol/L, or both for 24 hours. Error bars, SD for 3 independent experiments; **, P < 0.01. D, Western blot analysis of BAK and BAX immunoprecipitates and input lysates prepared from MV4–11 cells exposed to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 4 hours. Proteins were precipitated with AB1 and 6A7 antibodies, corresponding to activated BAK and BAX, respectively. E, Annexin V-FITC/PI analysis of control and MV4–11 cells in which BAK, BAX, or both BAK/BAX were knocked out using CRISPR technology as described in Materials and Methods were exposed to venetoclax 10 nmol/L, INK-128 100 nmol/L, or the combination for 24 hours. Error bars, SD for three independent experiments. *, P < 0.05; **, P < 0.01. F, Western blot analysis of MV4–11 cells following treatment with venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 24 hours as described in E. For Western blot studies, blots were stripped and re-probed for β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Figure 3.

Venetoclax/INK128 antileukemic synergism involves MCL-1 downregulation and activation of BAX and BAK. A, Western blot analysis of MCL-1 expression changes in MV4–11 cells following exposure (24 hours) to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination. B, MV4–11 cells ectopically expressing MCL-1 were generated and exposed, along with their empty-vector (EV) counterparts, to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 24 hours. Western blot analysis was then performed to monitor expression of cleaved PARP and MCL-1. C, Annexin V-FITC/PI analysis of EV and MCL-1 overexpressing MV4–11 cells treated with venetoclax 10 nmol/L, INK128 100 nmol/L, or both for 24 hours. Error bars, SD for 3 independent experiments; **, P < 0.01. D, Western blot analysis of BAK and BAX immunoprecipitates and input lysates prepared from MV4–11 cells exposed to venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 4 hours. Proteins were precipitated with AB1 and 6A7 antibodies, corresponding to activated BAK and BAX, respectively. E, Annexin V-FITC/PI analysis of control and MV4–11 cells in which BAK, BAX, or both BAK/BAX were knocked out using CRISPR technology as described in Materials and Methods were exposed to venetoclax 10 nmol/L, INK-128 100 nmol/L, or the combination for 24 hours. Error bars, SD for three independent experiments. *, P < 0.05; **, P < 0.01. F, Western blot analysis of MV4–11 cells following treatment with venetoclax 5 nmol/L, INK128 50 nmol/L, or the combination for 24 hours as described in E. For Western blot studies, blots were stripped and re-probed for β-actin to ensure equal loading and transfer. Results are representative of 3 separate experiments.

Close modal

BAX and BAK activation contributes to venetoclax/INK128 antileukemic activity

Immunoprecipitation studies were performed in MV4–11 and U937 cells to monitor activation of BAX and BAK following venetoclax/INK128 exposure. Combined treatment of MV4–11 cells with venetoclax/INK128 triggered a modest increase in BAK conformational change, an event associated with diminished co-immunoprecipitation with MCL-1 (Fig. 3D). Combined exposure also induced a more pronounced conformational change in BAX compared with untreated controls or to single-agent treatment, although the reduction in MCL-1 co-immunoprecipitating with BAX was less marked than that observed with BAK (Fig. 3D). A virtually identical response pattern was observed in U937 cells (Supplementary Fig. S6F).

To assess the functional significance of these events, MV4–11 cells were engineered using CRISPR technology to knockout BAK, BAX, and both BAK and BAX. BAX individual knockout and BAK/BAX dual knockout displayed dramatically reduced lethality following venetoclax/INK128 exposure, whereas cell death was reduced to a lesser but still significant (P < 0.05) extent in BAK individual knockout cells (Fig. 3E and F). Reductions in caspase-3 cleavage were concordant with these findings (Fig. 3F). Collectively, these findings argue that the antileukemic activity of the venetoclax/INK128 regimen involves activation of BAK and particularly BAX.

Venetoclax/INK128 synergism is observed in leukemic cells exhibiting acquired venetoclax resistance

Venetoclax-resistant MV4–11 cells were generated by continuously exposing cells to progressively higher concentrations of venetoclax. Two clones, designated MV4–11 R1 and R2, were generated that displayed minimal cell death at venetoclax concentrations of 500 or 1,000 nmol/L, concentrations that were lethal to the majority of control cells (Fig. 4A). Evidence of diminished caspase-3 and PARP cleavage confirmed these findings (Fig. 4B). Of note, resistant cells displayed increased basal activation of AKT (S473) and expression of MCL-1 accompanied by a pronounced reduction in BCL2 expression compared with controls (Fig. 4C). Significantly, in both resistant cell lines, INK128 and venetoclax interacted synergistically to induce cell death (Fig. 4D; actual flow data are shown in Supplementary Fig. S8A and S8B). These events were accompanied by marked AKT inactivation and downregulation of MCL-1 (Fig. 4E). Of note, when the R1 and R2-resistant lines were treated at the same (lower) concentrations used for sensitive MV4–11 cells, the cytotoxicity of the combination treatment was reduced compared with controls but was still significantly greater than that observed for single-drug treatment (Supplementary Fig. S9A and S9C).

Figure 4.

The INK128/venetoclax regimen displays synergism in leukemic cell lines exhibiting acquired venetoclax resistance. MV4–11 cells were cultured in the presence of increasing venetoclax concentrations over a period of 2 months. A, Assessment of cell viability using Annexin V-FITC/PI after treating control MV4–11 cells and 2 acquired venetoclax-resistant MV4–11 cells with venetoclax 50, 100, 500 nmol/L, and 1 μmol/L for 48 hours.**, P < 0.01 in each case for values obtained in resistant groups versus the control group. B, Western blot analysis in control and 2 acquired venetoclax-resistant MV4–11 cells following exposure to venetoclax at 10, 100, and 1,000 nmol/L for 16 hours. C, Western blot analysis in control and 2 acquired venetoclax-resistant MV4–11 cell lines without treatment, D, Median dose effect analysis in 2 acquired venetoclax-resistant MV4–11 cell lines displays combination index values below 1.0, indicating synergism at dose ratio venetoclax:INK128 = 2:1 (48 hours). E, Western blot analysis in 2 acquired venetoclax-resistant MV4–11 cell lines following exposure to venetoclax 1 μmol/L, INK128 500 nmol/L, or the combination for 24 hours.

Figure 4.

The INK128/venetoclax regimen displays synergism in leukemic cell lines exhibiting acquired venetoclax resistance. MV4–11 cells were cultured in the presence of increasing venetoclax concentrations over a period of 2 months. A, Assessment of cell viability using Annexin V-FITC/PI after treating control MV4–11 cells and 2 acquired venetoclax-resistant MV4–11 cells with venetoclax 50, 100, 500 nmol/L, and 1 μmol/L for 48 hours.**, P < 0.01 in each case for values obtained in resistant groups versus the control group. B, Western blot analysis in control and 2 acquired venetoclax-resistant MV4–11 cells following exposure to venetoclax at 10, 100, and 1,000 nmol/L for 16 hours. C, Western blot analysis in control and 2 acquired venetoclax-resistant MV4–11 cell lines without treatment, D, Median dose effect analysis in 2 acquired venetoclax-resistant MV4–11 cell lines displays combination index values below 1.0, indicating synergism at dose ratio venetoclax:INK128 = 2:1 (48 hours). E, Western blot analysis in 2 acquired venetoclax-resistant MV4–11 cell lines following exposure to venetoclax 1 μmol/L, INK128 500 nmol/L, or the combination for 24 hours.

Close modal

Venetoclax-resistant MOLM-13 cells (Supplementary Fig. S7A and S7B) exhibited modest increases in p-AKT (S473), BCL-xL, and MCL-1 expression compared with controls, but no decline in BCL2 levels (Supplementary Fig. S7C). Very marked synergism between INK128 and venetoclax was observed in both resistant clones (Supplementary Fig. S7D; actual flow data are shown in Supplementary Fig. S8C and S8D), accompanied by inactivation of AKT and downregulation of MCL-1 (Supplementary Fig. S7E). Similar to MV4–11 R1 and R2, synergistic cell killing was reduced in MOLM-13 R1 and R2 compared with control MOLM-13 (Supplementary Fig. S9B and S9D). These findings demonstrate that INK128 and venetoclax interact synergistically in cells resistant to venetoclax via disparate mechanisms, and suggest that inactivation of AKT and downregulation of MCL-1 may be implicated in this phenomenon.

The venetoclax/INK128 regimen increases cell death in primary AML cells but not in normal CD34+ cells

Effects of the venetoclax/INK128 regimen were examined in primary patient-derived AML cells in vitro. The clinical features of patients donating specimens are listed in Supplementary Tables S1 and S2. In a representative specimen, immunofluorescence staining with CD34 and 7-AAD showed a marked increase in 7-AAD staining (red) colocalizing with CD34 following combined compared with single-agent treatment (Fig. 5A). In both the bulk leukemia cell population (ref. 33; CD45dim, side scatter low, CD34+; N = 11; Fig. 5B) and more primitive leukemia cell population [ref. 24; CD34+ CD38 CD123+ (ref. 34) N = 5; Fig. 5C], cell viability was significantly decreased in the combined versus the single-treatment groups. In addition, studies were performed using a limited number of specimens treated with 10 or 50 nmol/L venetoclax. As shown in Supplementary Fig. S10A–S10D, results were generally similar to those employing 5 nmol/L venetoclax, for example, combined treatment induced significantly more cell death than individual drug exposure. In marked contrast, no significant difference was observed between treatment groups in the case of normal CD34+ cord blood hematopoietic cells (Fig. 5D). Finally, Western blot analysis for cleaved PARP and caspase 3, MCL-1, and phosphorylated AKT in two specimens for which sufficient cells were available displayed similar patterns as observed in leukemia cell lines (Fig. 5E).

Figure 5.

Combined INK128/venetoclax exposure enhances cell death in primary AML patient samples in vitro. A, Primary AML patient samples were treated for 16 hours with venetoclax 5 nmol/L, INK128 100 nmol/L, or the combination. Cells were stained with hCD45-PE/Cy7 and DAPI. Images were obtained with an IX71-Olympus inverted system microscope at ×200 magnification. B, Assessment of cell viability (Annexin V/7-AAD) in the bulk leukemic cell population (CD34+/SS low/CD45 dim) for 11 primary AML specimens following 16-hour treatment with venetoclax and INK128 alone or in combination. Venetoclax concentrations were 5 nmol/L, whereas INK128 was administered at 100 nmol/L. The median values for combined treatment were significantly lower than values for either agent alone. C, Assessment of cell viability using Annexin V/7-AAD in 5 primary AML specimens exhibiting a more primitive phenotype (CD34+CD123+CD38) following 16-hour exposure to venetoclax 5 nmol/L and INK128 100 nmol/L alone or in combination. The median values for combined treatment were significantly lower than values for either agent alone. #, P < 0.05; ##, P < 0.01 in each case for values obtained in the single-agent treatment group compared with the control group. *, P < 0.05; **, P < 0.01, in each case for values obtained in co-treatment group versus single-agent treatment. D, Normal mononuclear hematopoietic cells were isolated from umbilical cord blood of 8 subjects and exposed to venetoclax 5 nmol/L and INK128 100 nmol/L alone or in combination for 16 hours, after which, viability was assessed selectively in the CD34+ cell population by Annexin V/7-AAD staining. Cell viabilities were not different between single-agent treatment groups and the combined treatment group. E, Western blot analysis of the indicated proteins in representative primary patient samples following 16 hours exposure to venetoclax 5 nmol/L, INK128 100 nmol/L, or both for 16 hours. For Western blot studies, blots were stripped and re-probed for GAPDH to ensure equal loading and transfer.

Figure 5.

Combined INK128/venetoclax exposure enhances cell death in primary AML patient samples in vitro. A, Primary AML patient samples were treated for 16 hours with venetoclax 5 nmol/L, INK128 100 nmol/L, or the combination. Cells were stained with hCD45-PE/Cy7 and DAPI. Images were obtained with an IX71-Olympus inverted system microscope at ×200 magnification. B, Assessment of cell viability (Annexin V/7-AAD) in the bulk leukemic cell population (CD34+/SS low/CD45 dim) for 11 primary AML specimens following 16-hour treatment with venetoclax and INK128 alone or in combination. Venetoclax concentrations were 5 nmol/L, whereas INK128 was administered at 100 nmol/L. The median values for combined treatment were significantly lower than values for either agent alone. C, Assessment of cell viability using Annexin V/7-AAD in 5 primary AML specimens exhibiting a more primitive phenotype (CD34+CD123+CD38) following 16-hour exposure to venetoclax 5 nmol/L and INK128 100 nmol/L alone or in combination. The median values for combined treatment were significantly lower than values for either agent alone. #, P < 0.05; ##, P < 0.01 in each case for values obtained in the single-agent treatment group compared with the control group. *, P < 0.05; **, P < 0.01, in each case for values obtained in co-treatment group versus single-agent treatment. D, Normal mononuclear hematopoietic cells were isolated from umbilical cord blood of 8 subjects and exposed to venetoclax 5 nmol/L and INK128 100 nmol/L alone or in combination for 16 hours, after which, viability was assessed selectively in the CD34+ cell population by Annexin V/7-AAD staining. Cell viabilities were not different between single-agent treatment groups and the combined treatment group. E, Western blot analysis of the indicated proteins in representative primary patient samples following 16 hours exposure to venetoclax 5 nmol/L, INK128 100 nmol/L, or both for 16 hours. For Western blot studies, blots were stripped and re-probed for GAPDH to ensure equal loading and transfer.

Close modal

Antileukemic effects of the venetoclax/INK128 regimen in vivo

To assess the in vivo anti-leukemic activity of the venetoclax/INK128 regimen, NOD/SCID-gamma mice systemically bearing luciferase-labeled MV4–11 cell–derived xenografts were used. Coadministration of venetoclax (80 mg/kg) and INK128 (0.5 mg/kg) significantly (P < 0.05 vs. single agents) reduced the leukemia cell burden in vivo whereas single agents had only modest activity (Supplementary Fig. S11A and S11B). Survival was also significantly prolonged in the combination treatment arm compared with the placebo and single-agent arms (Supplementary Fig. S11C) without significant difference in body weight (Supplementary Fig. S11D). Similar tumor growth reduction was also observed in a flank tumor model involving U937 cells (Supplementary Fig. S12A and S12B). Western blot analysis of flank model tumors showed sharp increases in caspase-3 cleavage and downregulation of MCL-1, p-AKT, and p-4EBP1 expression with combined treatment as observed in leukemia cell lines (Supplementary Fig. S12C). Again, we did not observe significant difference in body weight among treatment groups (Supplementary Fig. S12D).

This combination treatment strategy was evaluated in a PDX model. NSG-SGM3 (stem cell factor, GMCSF and IL03) mice were injected with primary AML cells and treated with venetoclax (80 mg/kg) ± INK128 (0.5 mg/kg) when human CD45+ cells appeared stably in the peripheral blood (Supplementary Fig. S14A and S14B). In vitro exposure (24 hours) of these cells with INK128 + venetoclax showed a significant reduction in cell viability compared with single-agent treatment (Supplementary Fig. S13A and S13B). Mice were treated for 6 weeks and sacrificed at day 50 of treatment. At the time of sacrifice, CD45-positive human-derived cells in bone marrow were significantly reduced in the combined treatment group compared with each single-agent and control cohorts (Fig. 6A and B) whereas body weight was not significantly different across groups before and during the entire treatment interval (Fig. 6C). Similar findings were obtained by IHC (Fig. 6D, stained with anti-human CD45) and immunofluorescence analysis of bone marrow cells (Supplementary Fig. S14C). Collectively, these results indicate that combined INK128/venetoclax treatment is both tolerable and effective in xenograft and PDX AML models.

Figure 6.

Combined venetoclax/INK128 exposure inhibits leukemic cell expansion in a PDX model. A, NOD/SCID-gamma SCF/GM-CSF/IL3 (NSG-SGM3) mice (3 mice/group) were inoculated via tail vein with 4 ×106 primary patient AML cells exhibiting a mutation in CEBPA and in Notch 1. After human CD45+ cells were detectable in the peripheral blood, venetoclax (80 mg/kg, oral) ± INK128 (0.5 mg/kg, oral) was administered 3 days/week for 6 weeks. Control animals were administered equal volumes of vehicle. CD45+ cells in the peripheral blood were monitored every two weeks. After 6-week treatment with venetoclax ± INK128, animals were sacrificed and human CD45+ cells in the marrow were quantified by flow cytometry. B, Data are shown as the mean percentage ± SD of CD45+ cells. *, P < 0.05; ***, P < 0.001. C, Body weights were monitored every other day during the treatment interval. Data are shown as the mean ± SD. D, Representative bone marrow IHC visualization. 5-μm-thick sections of paraffin-embedded, formalin-fixed tissues were stained with anti-human CD45 antibodies and positive cells are indicated in arrows. Images were obtained with a BX41-Olympus fluorescence microscope at ×200 magnification.

Figure 6.

Combined venetoclax/INK128 exposure inhibits leukemic cell expansion in a PDX model. A, NOD/SCID-gamma SCF/GM-CSF/IL3 (NSG-SGM3) mice (3 mice/group) were inoculated via tail vein with 4 ×106 primary patient AML cells exhibiting a mutation in CEBPA and in Notch 1. After human CD45+ cells were detectable in the peripheral blood, venetoclax (80 mg/kg, oral) ± INK128 (0.5 mg/kg, oral) was administered 3 days/week for 6 weeks. Control animals were administered equal volumes of vehicle. CD45+ cells in the peripheral blood were monitored every two weeks. After 6-week treatment with venetoclax ± INK128, animals were sacrificed and human CD45+ cells in the marrow were quantified by flow cytometry. B, Data are shown as the mean percentage ± SD of CD45+ cells. *, P < 0.05; ***, P < 0.001. C, Body weights were monitored every other day during the treatment interval. Data are shown as the mean ± SD. D, Representative bone marrow IHC visualization. 5-μm-thick sections of paraffin-embedded, formalin-fixed tissues were stained with anti-human CD45 antibodies and positive cells are indicated in arrows. Images were obtained with a BX41-Olympus fluorescence microscope at ×200 magnification.

Close modal

BCL2 inhibitor monotherapy exerts only modest therapeutic benefit in AML, and current clinical approval in this disease involves combination with hypomethylating agents or low-dose cytarabine (8). Mechanisms of resistance to venetoclax include MCL-1 upregulation through activation of various pathways (35, 36), predominance of monocytic phenotype expansion (37), acquired BAX mutations (38), and TP53 mutations (intrinsic resistance; ref. 39). We and others have previously reported synergistic interactions between BCL2 ± BCL-xL and PI3K/AKT/mTORC pathway inhibitors in AML (24, 25) and other hematopoietic malignancies (40). However, the ability of dual mTORC1/2 inhibitors to potentiate the activity of venetoclax in AML cells, including those displaying intrinsic or acquired venetoclax resistance, has not yet been investigated. The present findings indicate that a strategy combining venetoclax with a dual mTORC1/2 inhibitor is effective in these settings as well as in multiple in vivo AML models.

INK128 is a dual mTORC1/2 inhibitor that potently inhibits Ser473 AKT phosphorylation, an event required for TORC2 activation (41). mTORC1/2 inhibitors exhibit theoretical advantages over clinically approved selective mTORC1 inhibitors such as rapamycin through multiple possible mechanisms, including more pronounced inhibition of protein translation (19, 41, 42), more effective downregulation of MCL-1 (24), and prevention of the compensatory rebound AKT activation observed with rapamycin (43). In the current study, combining venetoclax with rapamycin was not associated with synergistic induction of cell death, whereas combining venetoclax with INK128 dramatically induced apoptosis in multiple leukemia cell lines, including those resistant to venetoclax, as well as patient specimens in vitro. Such findings raise the possibility that a dual mTORC1/2 inhibitor such as INK128 may be more effective when combined with venetoclax than pure mTORC1 inhibitors in patients with AML.

It is noteworthy that INK128 alone or in combination with venetoclax effectively suppressed phosphorylation of AKT and 4EBP1 in multiple AML models. Importantly, INK128 significantly enhanced venetoclax-mediated cell killing in cells exhibiting constitutively active AKT. In sharp contrast, a PI3K inhibitor (copanlisib), which we and others have shown to increase venetoclax lethality in malignant hematopoietic cells (25, 44) failed to do so. Similar findings were obtained with the AKT inhibitor MK2206. Moreover, INK128 was more effective than either of these agents in downregulating phospho-AKT expression in cells expressing constitutively active AKT. Dual mTORC1/2 inhibition by INK128 also diminished 4EBP1 phosphorylation in constitutively active AKT cell lines, in contrast with copanlisib and MK2206. These findings most likely reflect the ability of dual mTORC1/2 inhibitors to act at sites both upstream and downstream of AKT (14). Inhibition of AKT results in MCL-1 degradation through a GSKβ-dependent mechanism as we and others have previously reported (45, 46). In addition, deactivation of p4EBP1 by blocking phosphorylation plays diverse roles in cellular survival, including regulation of autophagy, transcription, and selective translation (47). Importantly, as MCL-1 has a very short half-life (e.g., 2–3 hours), inhibition of translation represents a potent stimulus for MCL-1 downregulation (28). It is therefore plausible that the capacity of INK128, but not MK2206 or copanlisib to downregulate p4EBP1 may contribute to the ability of the dual mTORC1/2 inhibitor but not MK2206 or copanlisib to circumvent the protective actions of constitutive AKT activation. Given frequent upregulation/activation of AKT in AML (12), it is tempting to speculate that combining venetoclax with dual mTORC1/2 inhibitors may be particularly effective against a subset of leukemic cells in which AKT is constitutively activated. Efforts to test this concept are currently underway.

The ability of BCL2 inhibitors to increase expression levels of MCL-1, including in vivo, is well described previously (48), although the mechanism underlying this phenomenon remains to be elucidated. Such a compensatory process represents an important mechanism of venetoclax resistance (36). It has been shown that MCL-1 (± BCL-xL) downregulation/knockdown can re-sensitize venetoclax-resistant AML cell lines to this agent (49). Consistent with these findings, ectopic expression of MCL-1 markedly protected leukemic cells from the INK128/venetoclax regimen. Taken together, such findings argue that the ability of INK128 to prevent venetoclax-mediated MCL-1 upregulation, and instead downregulate expression of this protein, are likely to be implicated in the antileukemic activity of this regimen. Furthermore, induction of leukemic cell death by the INK128/venetoclax regimen was functionally dependent upon BAK and particularly BAX activation, based on the observation that BAK and BAX knock-out cells were highly resistant to the INK128/venetoclax regimen. In the case of BAK, this may reflect the observed reduction in binding of downregulated MCL-1 to this protein, culminating in MOMP (50).

Interestingly, leukemic cells displaying acquired venetoclax resistance exhibited activation of AKT accompanied by increased expression of MCL-1, and these events were reversed by INK128 administration. This may stem from the ability of AKT inhibition to enhance MCL-1 degradation through a GSK-dependent process (51) and by interfering with 4EBP1-dependent protein synthesis, leading to downregulation of short-lived proteins such as MCL-1 (52). Although the magnitude of specific perturbations in relevant proteins varied between resistant cell lines, common features included marked increases in the relative expression levels of MCL-1/BCL2, and increased expression of p-AKT. The former findings are consistent with observations that patients with multiple myeloma whose cells exhibit low BCL2/MCL-1 ratio are likely to be resistant to venetoclax (53). The higher baseline MCL-1 expression in acquired venetoclax-resistant cell lines raised the possibility that they might be more sensitive to INK128 due to their dependence upon this protein. However, the absolute cytotoxicity of dual treatment was reduced compared with non-resistant cell lines, arguing against this notion. Notably, synergistic interactions between INK128 and venetoclax accompanied by p-AKT and MCL-1 downregulation in leukemic cells displaying acquired venetoclax resistance were recapitulated in cell lines (e.g., U937) exhibiting intrinsic venetoclax resistance. Taken together, such findings raise the possibility that the INK128/venetoclax strategy may act through a mechanism-based manner to induce leukemic cell death in venetoclax-resistant cells.

Administration of INK128 significantly increased the lethality of venetoclax toward primary AML blasts in association with downregulation of MCL-1 and inactivation of AKT, but had little or no effect on normal hematopoietic cells (CD34+). The basis for this selectivity is unclear, but may reflect the increased dependence of leukemic cells, including primitive leukemic progenitors, on BCL2, MCL-1, and activated AKT for survival compared with their normal counterparts (54). Determining whether this strategy will be particularly effective against leukemic cells exhibiting basal AKT activation and potentially addicted to this pathway for survival will require analysis of a considerably larger number of specimens. However, the finding that leukemic cells genetically engineered to express constitutively active AKT were highly susceptible to the INK128/venetoclax regimen raises the possibility that this may be the case.

Notably, the INK128/venetoclax regimen was well tolerated in mice, and resulted in a significantly greater reduction in leukemic cell burden compared with single-agent treatment in flank and systemic xenograft as well as AML PDX models. Such findings are consistent with the previously observed in vitro selectivity of this strategy. Significantly, leukemic cells extracted from animals receiving both agents exhibited several of the perturbations observed in vitro, for example, downregulation of p-AKT, p-4EBP1, and MCL-1, arguing that mechanisms responsible for enhanced antileukemic effects observed in vitro can be recapitulated in the in vivo setting.

In summary, the present findings demonstrate that dual mTORC1/2 inhibition robustly increases venetoclax antileukemic activity through an MCL-1 and BAX/BAK-dependent mechanism, including in cells resistant to venetoclax or expressing constitutively active AKT. It is also active against primary leukemic but not normal cells, as well as in multiple AML model systems. The recent success of the HMA/venetoclax regimen in AML has prompted the search for new strategies, particularly those targeting MCL-1, to increase the efficacy of venetoclax, including co-administration of novel MCL-1 inhibitors (55). The present observations argue that combining dual mTORC1/2 inhibitors with venetoclax, if tolerable, may represent a promising addition to the therapeutic armamentarium for AML.

S. Grant reports grants from NCI during the conduct of the study. No disclosures were reported by the other authors.

T. Satta: Conceptualization, resources, data curation, software, funding acquisition, validation, investigation, visualization, methodology, writing–original draft, project administration. L. Li: Conceptualization, resources, data curation, software, formal analysis, validation, investigation, visualization, methodology, writing–original draft, project administration, writing–review and editing. S.L. Chalasani: Investigation, methodology. X. Hu: Investigation, methodology. J. Nkwocha: Investigation, methodology. K. Sharma: Investigation, methodology. M. Kmieciak: Resources, data curation, formal analysis. M. Rahmani: Methodology, writing–review and editing. L. Zhou: Investigation, visualization. S. Grant: Conceptualization, supervision, funding acquisition, validation, writing–original draft, project administration.

Supported by R01CA205607, R01CA167708, Leukemia and Lymphoma Society of America #6472–15, P30CA16059 (to S. Grant), and Rising Scholar program by Virginia Commonwealth University (to T. Satta).

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

1.
Carter
JL
,
Hege
K
,
Yang
J
,
Kalpage
HA
,
Su
Y
,
Edwards
H
, et al
.
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.
Signal Transduct Target Ther
2020
;
5
:
288
.
2.
Saxena
K
,
DiNardo
C
,
Daver
N
,
Konopleva
M
.
SOHO state of the art updates and next questions: harnessing apoptosis in AML
.
Clin Lymphoma Myeloma Leuk
2022
;
22
:
133
9
.
3.
Shangary
S
,
Johnson
DE
.
Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family
.
Leukemia
2003
;
17
:
1470
81
.
4.
Bhola
PD
,
Letai
A
.
Mitochondria-judges and executioners of cell death sentences
.
Mol Cell
2016
;
61
:
695
704
.
5.
Oltersdorf
T
,
Elmore
SW
,
Shoemaker
AR
,
Armstrong
RC
,
Augeri
DJ
,
Belli
BA
, et al
.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
.
Nature
2005
;
435
:
677
81
.
6.
Schoenwaelder
SM
,
Jarman
KE
,
Gardiner
EE
,
Hua
M
,
Qiao
J
,
MJ
, et al
.
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
.
Blood
2011
;
118
:
1663
74
.
7.
Souers
AJ
,
Leverson
JD
,
Boghaert
ER
,
Ackler
SL
,
Catron
ND
,
Chen
J
, et al
.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
.
Nat Med
2013
;
19
:
202
8
.
8.
Konopleva
M
,
Pollyea
DA
,
Potluri
J
,
Chyla
B
,
Hogdal
L
,
Busman
T
, et al
.
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
.
Cancer Discov
2016
;
6
:
1106
17
.
9.
DiNardo
CD
,
Jonas
BA
,
Pullarkat
V
,
Thirman
MJ
,
Garcia
JS
,
Wei
AH
, et al
.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
.
N Engl J Med
2020
;
383
:
617
29
.
10.
Chen
S
,
Dai
Y
,
Harada
H
,
Dent
P
,
Grant
S
.
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation
.
Cancer Res
2007
;
67
:
782
91
.
11.
Bajpai
R
,
Matulis
SM
,
Wei
C
,
Nooka
AK
,
Von Hollen
HE
,
Lonial
S
, et al
.
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
.
Oncogene
2016
;
35
:
3955
64
.
12.
Martelli
AM
,
Evangelisti
C
,
Chiarini
F
,
McCubrey
JA
.
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
.
Oncotarget
2010
;
1
:
89
103
.
13.
Dermit
M
,
Casado
P
,
Rajeeve
V
,
Wilkes
EH
,
Foxler
DE
,
Campbell
H
, et al
.
Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition
.
Oncogene
2017
;
36
:
2762
74
.
14.
Hirao
A
,
Hoshii
T
.
Mechanistic/mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia
.
Cancer Sci
2013
;
104
:
977
82
.
15.
Voss
MH
,
Molina
AM
,
Motzer
RJ
.
mTOR inhibitors in advanced renal cell carcinoma
.
Hematol Oncol Clin North Am
2011
;
25
:
835
52
.
16.
Recher
C
,
Beyne-Rauzy
O
,
Demur
C
,
Chicanne
G
,
Dos Santos
C
,
Mas
VM
, et al
.
Antileukemic activity of rapamycin in acute myeloid leukemia
.
Blood
2005
;
105
:
2527
34
.
17.
Tamburini
J
,
Green
AS
,
Bardet
V
,
Chapuis
N
,
Park
S
,
Willems
L
, et al
.
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
.
Blood
2009
;
114
:
1618
27
.
18.
Rodrik-Outmezguine
VS
,
Chandarlapaty
S
,
Pagano
NC
,
Poulikakos
PI
,
Scaltriti
M
,
Moskatel
E
, et al
.
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
.
Cancer Discov
2011
;
1
:
248
59
.
19.
Maiso
P
,
Liu
Y
,
Morgan
B
,
Azab
AK
,
Ren
P
,
Martin
MB
, et al
.
Defining the role of TORC1/2 in multiple myeloma
.
Blood
2011
;
118
:
6860
70
.
20.
Pike
KG
,
Malagu
K
,
Hummersone
MG
,
Menear
KA
,
Duggan
HM
,
Gomez
S
, et al
.
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014
.
Bioorg Med Chem Lett
2013
;
23
:
1212
6
.
21.
Burris
HA
III
,
Kurkjian
CD
,
Hart
L
,
Pant
S
,
Murphy
PB
,
Jones
SF
, et al
.
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
.
Cancer Chemother Pharmacol
2017
;
80
:
261
73
.
22.
Riess
JW
,
Frankel
P
,
Shackelford
D
,
Dunphy
M
,
Badawi
RD
,
Nardo
L
, et al
.
Phase 1 trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in patients with advanced NSCLC (NCI 10327): rationale and study design
.
Clin Lung Cancer
2021
;
22
:
67
70
.
23.
Koca
E
,
Niravath
PA
,
Ensor
J
,
Patel
TA
,
Li
X
,
Hemati
P
, et al
.
ANETT: phase II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
.
Breast Cancer Res Treat
2021
;
188
:
433
9
.
24.
Rahmani
M
,
Aust
MM
,
Hawkins
E
,
Parker
RE
,
Ross
M
,
Kmieciak
M
, et al
.
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 downregulation and AKT inactivation
.
Haematologica
2015
;
100
:
1553
63
.
25.
Rahmani
M
,
Nkwocha
J
,
Hawkins
E
,
Pei
X
,
Parker
RE
,
Kmieciak
M
, et al
.
Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells
.
Cancer Res
2018
;
78
:
3075
86
.
26.
Cheng
Z
,
Gong
Y
,
Ma
Y
,
Lu
K
,
Lu
X
,
Pierce
LA
, et al
.
Inhibition of BET bromodomain targets genetically diverse glioblastoma
.
Clin Cancer Res
2013
;
19
:
1748
59
.
27.
Rahmani
M
,
Anderson
A
,
Habibi
JR
,
Crabtree
TR
,
Mayo
M
,
Harada
H
, et al
.
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
.
Blood
2009
;
114
:
4507
16
.
28.
Rahmani
M
,
Davis
EM
,
Bauer
C
,
Dent
P
,
Grant
S
.
Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
J Biol Chem
2005
;
280
:
35217
27
.
29.
Chou
TC
.
Drug combination studies and their synergy quantification using the Chou–Talalay method
.
Cancer Res
2010
;
70
:
440
6
.
30.
Populo
H
,
Lopes
JM
,
Soares
P
.
The mTOR signalling pathway in human cancer
.
Int J Mol Sci
2012
;
13
:
1886
918
.
31.
Patel
VM
,
Balakrishnan
K
,
Douglas
M
,
Tibbitts
T
,
Xu
EY
,
Kutok
JL
, et al
.
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
.
Leukemia
2017
;
31
:
1872
81
.
32.
Yecies
D
,
Carlson
NE
,
Deng
J
,
Letai
A
.
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
.
Blood
2010
;
115
:
3304
13
.
33.
Haycocks
NG
,
Lawrence
L
,
Cain
JW
,
Zhao
XF
.
Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia
.
Cytometry B Clin Cytom
2011
;
80
:
221
9
.
34.
Vergez
F
,
Green
AS
,
Tamburini
J
,
Sarry
JE
,
Gaillard
B
,
Cornillet-Lefebvre
P
, et al
.
High levels of CD34+CD38low/–CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
.
Haematologica
2011
;
96
:
1792
8
.
35.
Zhang
HJ
,
Wilmot
B
,
Bottomly
D
,
Kurtz
SE
,
Eide
CA
,
Damnernsawad
A
, et al
.
Biomarkers predicting venetoclax sensitivity and strategies for venetoclax combination treatment
.
Blood 2018
;
132
:
175
.
36.
Konopleva
MY
.
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax
.
Best Pract Res Clin Haematol
2021
;
34
:
101251
.
37.
Pei
S
,
Pollyea
DA
,
Gustafson
A
,
Stevens
BM
,
Minhajuddin
M
,
Fu
R
, et al
.
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
.
Cancer Discov
2020
;
10
:
536
51
.
38.
Moujalled
DM
,
Brown
FC
,
Pomilio
G
,
Anstee
NS
,
Litalien
V
,
Thompson
ER
, et al
.
Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia
.
Blood
2020
;
136
:
7
8
.
39.
Kim
K
,
Maiti
A
,
Loghavi
S
,
Pourebrahim
R
,
Kadia
TM
,
Rausch
CR
, et al
.
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax
.
Cancer
2021
;
127
:
3772
81
.
40.
Bojarczuk
K
,
Wienand
K
,
Ryan
JA
,
Chen
L
,
Villalobos-Ortiz
M
,
Mandato
E
, et al
.
Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
.
Blood
2019
;
133
:
70
80
.
41.
Sarbassov
DD
,
Guertin
DA
,
Ali
SM
,
Sabatini
DM
.
Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex
.
Science
2005
;
307
:
1098
101
.
42.
Janes
MR
,
Vu
C
,
Mallya
S
,
Shieh
MP
,
Limon
JJ
,
Li
LS
, et al
.
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
.
Leukemia
2013
;
27
:
586
94
.
43.
O'Reilly
KE
,
Rojo
F
,
She
QB
,
Solit
D
,
Mills
GB
,
Smith
D
, et al
.
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
.
Cancer Res
2006
;
66
:
1500
8
.
44.
Choudhary
GS
,
Al-Harbi
S
,
Mazumder
S
,
Hill
BT
,
Smith
MR
,
Bodo
J
, et al
.
MCL-1 and BCL-xL–dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
.
Cell Death Dis
2015
;
6
:
e1593
.
45.
Rahmani
M
,
Aust
MM
,
Attkisson
E
,
Ferreira-Gonzalez
A
,
Grant
S
.
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism
.
Cancer Res
2013
;
73
:
1340
51
.
46.
Maurer
U
,
Charvet
C
,
Wagman
AS
,
Dejardin
E
,
Green
DR
.
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
.
Mol Cell
2006
;
21
:
749
60
.
47.
Qin
X
,
Jiang
B
,
Zhang
Y
.
4E-BP1, a multifactor regulated multifunctional protein
.
Cell Cycle
2016
;
15
:
781
6
.
48.
Zhao
J
,
Niu
X
,
Li
X
,
Edwards
H
,
Wang
G
,
Wang
Y
, et al
.
Inhibition of CHK1 enhances cell death induced by the Bcl-2–selective inhibitor ABT-199 in acute myeloid leukemia cells
.
Oncotarget
2016
;
7
:
34785
99
.
49.
Lin
KH
,
Winter
PS
,
Xie
A
,
Roth
C
,
Martz
CA
,
Stein
EM
, et al
.
Targeting MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia
.
Sci Rep
2016
;
6
:
27696
.
50.
Willis
SN
,
Chen
L
,
Dewson
G
,
Wei
A
,
Naik
E
,
Fletcher
JI
, et al
.
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
.
Genes Dev
2005
;
19
:
1294
305
.
51.
Thomas
LW
,
Lam
C
,
Edwards
SW
.
Mcl-1; the molecular regulation of protein function
.
FEBS Lett
2010
;
584
:
2981
9
.
52.
Hsieh
AC
,
Costa
M
,
Zollo
O
,
Davis
C
,
Feldman
ME
,
Testa
JR
, et al
.
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E
,
Cancer Cell
2010
;
17
:
249
61
.
53.
Gong
JN
,
Khong
T
,
Segal
D
,
Yao
Y
,
Riffkin
CD
,
Garnier
JM
, et al
.
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
.
Blood
2016
;
128
:
1834
44
.
54.
Park
S
,
Chapuis
N
,
Tamburini
J
,
Bardet
V
,
Cornillet-Lefebvre
P
,
Willems
L
, et al
.
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
,
Haematologica
2010
;
95
:
819
28
.
55.
Carter
BZ
,
Mak
PY
,
Tao
W
,
Zhang
Q
,
Ruvolo
V
,
Kuruvilla
VM
, et al
.
Maximal activation of apoptosis signaling by cotargeting antiapoptotic proteins in BH3 mimetic-resistant AML and AML stem cells
.
Mol Cancer Ther
2022
;
21
:
879
89
.